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Abstract: The mechanism of gap junction enhancer (PQ1) induced cytotoxicity is thought to
be attributed to the change in connexin 43 (Cx43) expression; therefore, the effects of Cx43
modulation in cell survival were investigated in mammary carcinoma cells (FMC2u) derived
from a malignant neoplasm of a female FVB/N-Tg(MMTV-PyVT)634Mul/J (PyVT) transgenic
mouse. PQ1 was determined to have an IC50 of 6.5 µM in FMC2u cells, while inducing an
upregulation in Cx43 expression. The effects of Cx43 modulation in FMC2u cell survival was
determined through transfection experiments with Cx43 cDNA, which induced an elevated level
of protein expression similar to that seen with PQ1 exposure, or siRNA to silence Cx43 protein
expression. Overexpression or silencing of Cx43 led to a reduction or an increase in cell viability,
respectively. The mitogen-activated protein kinase (MAPK) family has been implicated in the
regulation of cell survival and cell death; therefore, the gap junctional intercellular communication
(GJIC)-independent function of PQ1 and Cx43 in the Raf/Mitogen-activated protein kinase/ERK
kinase/extracellular-signal-regulated kinase (Raf-MEK-ERK) cascade of cellular survival and p38
MAPK-dependent pathway of apoptosis were explored. PQ1 treatment activated p44/42 MAPK,
while the overexpression of Cx43 resulted in a reduced expression. This suggests that PQ1 affects
the Raf-MEK-ERK cascade independent of Cx43 upregulation. Both overexpression of Cx43 and
PQ1 treatment stimulated an increase in the phosphorylated form of p38-MAPK, reduced levels
of the anti-apoptotic protein Bcl-2, and increased the cleavage of pro-caspase-3. Silencing of Cx43
protein expression led to a reduction in the phosphorylation of p38-MAPK and an increase in Bcl-2
expression. The mechanism behind PQ1-induced cytotoxicity in FMC2u mammary carcinoma cells
is thought to be attributed to the change in Cx43 expression. Furthermore, PQ1-induced apoptosis
through the upregulation of Cx43 may depend on p38 MAPK, highlighting that the effect of PQ1 on
gap junctions as well as cellular survival via a MAPK-dependent pathway.
Keywords: connexin 43; PQ1; gap junction; apoptosis; MAPK
1. Introduction
Breast cancer is the most common cancer in women worldwide, and mortality from breast cancer
is consistent due to tumor invasion and metastasis [1]. Cell and animal models help to further the
understanding of breast cancer pathogenesis and provide insight into treatment options. In vivo
studies are crucial for drug development, but many drugs do not translate from in vitro to in vivo.
The use of a cell line derived from an animal with clinical features of human breast cancer can be
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utilized to screen drugs prior to use in the animal itself. Although a number of breast cancer cell
lines has been established, a limited number of cell lines is available derived from a transgenic mouse
model of spontaneous mammary carcinomas. The establishment of such a line would provide another
method to study tumor growth and therapeutic effects despite genetic predisposition for cancer
formation. Previously, the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J (also known as PyVT)
was used as a model system for measuring tumor burden, drug sensitivity, and metastasis of mammary
carcinomas [2]. Here a new cell line, female mammary carcinoma cells (FMC2u), was established
from the primary tumor tissue resected from a late stage PyVT mouse with an aggressive, metastatic
phenotype. FMC2u was characterized by morphology, receptor expression levels, proliferative and
migratory abilities, invasiveness, and colony formation. The anticancer effects on FMC2u cell growth
were determined for gap junction enhancers (PQs).
Multiple molecular processes are affected by gap junctional intercellular communication (GJIC),
including proliferation, differentiation, migration and apoptosis [3,4]. One of the hallmarks of cancer
is the loss of GJIC and connexins, the gap junction proteins [5]. Connexins are therapeutic targets in
cancer treatment through both a GJIC-dependent mechanism and a GJIC-independent mechanism [6].
Connexins exhibit a tumor suppressive function via a GJIC-independent manner by interacting and
regulating molecules and genes involved in tumorigenesis [7]. The substituted quinolines (PQ1 and
PQ7) are gap junction enhancers that have been shown to significantly increase GJIC while reducing
breast cancer cell viability [8–10]. The inhibitory ability of PQs was tested on FMC2u cellular growth,
showing that PQ1 significantly reduced proliferation and viability while increasing Connexin 43 (Cx43)
expression. This observation suggests that Cx43 contributes to the anticancer effects of PQ1.
The role of Cx43 in PQ1 induced cytotoxicity was further determined via modulation of
expression by transfection experiments in FMC2u cells. Specifically we evaluated the effects of Cx43
modulation on the Raf/Mitogen-activated protein kinase/ERK kinase/extracellular-signal-regulated
kinase (Raf-MEK-ERK) cascade and the p38 mitogen-activated protein kinase (MAPK) apoptotic
pathway. The MAPKs are signaling pathways critical for the conversion of various extracellular signals
to biological responses [11]. In particular, extracellular-signal-regulated kinase (ERK) activation is
generally related to cell survival, while reports indicate that apoptosis is associated with the activation
of p38 MAPK [11–13]. This study explores the role of Cx43 in relation to PQ1 induced cytotoxicity.
2. Results
2.1. Morphology and Growth Characteristics of Female Mammary Carcinoma Cells (FMC2u)
Histologically, the parental tumor was classified as a late carcinoma composed of nests
of neoplastic cells that frequently mitosed (Figure 1A). Cells within the tumor contained large
pleomorphic nuclei and prominent nucleoli. Characteristic features of the cell line are similar to
the parental tumor type and have remained constant despite the number of passages. Cultured FMC2u
cells grew as adherent undifferentiated cells (Figure 1B). The nuclei varied in size and little cytoplasm
were observed. Cells grew as interlacing colonies with disorganized growth patterns. At heavy cell
density the cells were observed to pile upon each other.
Optimal growth conditions were determined via proliferation and viability tests. RPMI media
(with or without insulin) with 10% fetal bovine serum (FBS) was found to provide the best conditions
for both proliferation and viability of FMC2u (Data not shown). RPMI was used for all following
studies. The approximate doubling time was observed to be 24 h (Figure 1C). The growth rate
decreased at high cell densities. Invasiveness was determined by the use of transwells with an 8 micron
pore membrane. Cells were tested for movement from an insert with 0% FBS to a receiver with 10%
FBS RPMI media. Cells were able to transverse the membrane after 24 and 48 h of incubation (Data
not shown). Using a “wound” assay FMC2u were observed to migrate efficiently across an adherent
surface to form a monolayer of cells (Figure 1D). In 60 h, a 1 mm section was completely closed. Colony
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formation was determined by use of a soft agar assay in which individual cells were seen proliferating
in the agar matrix. Over a 15 day period, large colonies were formed (Figure 1E).
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Figure 1. Characteristics of mammary carcinoma (FMC2u) cells. (A) H&E of primary tumor isolated 
from late stage PyVT female at 40×, Scale bar = 50 µm; (B) Micrograph of FMC2u in cell culture at 20 
Nguyen, ×, Scale bar = 20 µm; (C) Proliferation of FMC2u cells with an approximate doubling time of 
24 h; (D) Migration assay. Red lines indicate a cross section “X” cut in the initial monolayer, 
approximately 1 mm in diameter. Cells were maintained in RPMI with 10% fetal bovine serum (FBS). 
Images taken every 12 h at 4×. Wound was completely closed by 60 h; (E) Colony formation in soft 
agar. 10,000 cells seeded on 0.8% agar RPMI and covered with 0.4% agar RPMI. Images were taken 
every 24 h at 10×. Purple circle follows the growth of a few cells at 48 h to a solid colony at 15 days. 
Scale bar = 100 µm. 
2.2. Protein Phenotype of FMC2u Cells 
FMC2u cells were determined to be of epithelial origin using the molecular markers E-cadherin, 
occludin, and claudin-1 (Figure 2A). Additionally, the hormone receptor profile was quantified by 
Western blot analysis which revealed low expression of estrogen receptors α (ERα) and β (ERβ), as 
well as the progesterone receptor (PR), with strong expression of human epidermal growth factor 
receptor 2 (HER2) (Figure 2B). 
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from late stage PyVT female at 40ˆ, Scal bar = 50 µm; (B) Micrograph of FMC2u in c ll culture at
20 Nguyen, ˆ, Scale bar = 20 µm; (C) Proliferation of FMC2u cells with an approximate doubling
time of 24 h; (D) Migration assay. Red lines indicate a cross section “X” cut in the initial monolayer,
approximately 1 mm in diameter. Cells were maintained in RPMI with 10% fetal bovine serum (FBS).
Images taken every 12 h at 4ˆ. Wound was completely closed by 60 h; (E) C lony formation in soft
agar. 10,000 cells seeded on 0.8% agar RPMI and covered with 0.4% agar RPMI. Images were taken
every 24 h at 10ˆ. Purple circle follows the growth of a few cells at 48 h to a solid colony at 15 days.
Scale bar = 100 µm.
2.2. Protein Phenotype of FMC2u Cells
FMC2u cells were determined to be of epithelial origin using the molecular markers E-cadherin,
occludin, and claudin-1 (Figure 2A). Additionally, the hormone receptor profile was quantified by
Western blot analysis which revealed low expression of estrogen receptors α (ERα) and β (ERβ), as
well as the progesterone receptor (PR), with strong expression of human epidermal growth factor
receptor 2 (HER2) (Figure 2B).
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Figure 2. A phenotypic profile of FMC2u cells. Western blot analysis of three different samples of 
FMC2u (#1–3). (A) Images of the epithelial markers E-cadherin, occludin, and claudin-1; (B) 
expression of estrogen receptor (ERα and ERβ), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2); and (C) expression of gap junction proteins (connexin 43 and 46) 
and molecular marker Bcl-2 are shown using antibodies against specific protein. Actin used as a 
loading control. 
Gap junction intercellular communication (GJIC) has an important function in maintaining 
tissue homeostasis. GJIC is the process in which small metabolites are shared directly by contiguous 
cells that have their cytoplasms connected by aqueous channels called gap junctions. FMC2u cells 
expressed both Cx43 and Cx46 (Figure 2C). 
Bcl-2 is an antiapoptotic protein that is a key regulator of apoptosis [14] and associated with  
low-grade, slowly proliferating, ER+ breast cancer [15,16]. Overexpression of Bcl-2 has been identified 
in a variety of malignancies and is one of the 21 genes used as a prognostic signature in Oncotype 
DX, a diagnostic test for the likely benefit from certain types of chemotherapy [17]. FMC2u cells were 
shown to have a high expression of Bcl-2 (Figure 2C). 
2.3. Effects of Treatment with Gap Junction Enhancers 
A class of substituted quinolines was described in Shi et al. [9,18,19] and the effects of the first 
and second generation compounds (PQ1 and PQ7, respectively) as gap junction enhancers in breast 
cancer cell lines have been explored in previous studies. 
2.4. Cellular Proliferation and Viability 
The gap junction enhancers were tested for their inhibitory capacity on FMC2u cells. PQ1 was 
shown to have an IC50 of 6.5 µM over a 24 h treatment period, while a 48 h treatment period required 
an increase to 8 µM to reduce viability by 50% (Figure 3A). This suggests that the effect of PQ1 on 
FMC2u cells is time and dose dependent. The effects of treatment were also seen in the total cell count 
after each treatment period (Figure 3B), indicating that the proliferative ability of the cells is 
compromised. PQ11 was shown to be ineffective at all concentrations tested (Data not shown). 
To determine if the observed reduction in growth and viability of FMC2u cells after PQ1 
treatment was due to activation of the apoptotic pathway, the expression of cleaved caspase-3 was 
examined. Apoptosis is a highly regulated cell suicide mechanism and the cleavage of protein 
substrates by caspases is unique to apoptotic cells. PQ1 treatment over a 24 h period led to a 
significant increase in cleaved caspase-3 expression at all concentrations tested (p-value1µM = 0.00556, 
p-value2.5µM = 0.00026, p-value5µM = 0.02237; Figure 3C). This indicates that PQ1 activates apoptosis in 
FMC2u cells. 
Figure 2. A phenotypic profile of FMC2u cells. Western blot analysis of three different samples of
FMC2u (#1–3). (A) Images of the epithelial markers E-cadherin, occludin, and claudin-1; (B) expression
of estrogen receptor (ERα and ERβ), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2); and (C) expression of gap junction proteins (connexin 43 and 46) and molecular
marker Bcl-2 are shown using antibodies against specific protein. Actin used as a loading control.
Gap junction intercellular communication (GJIC) has an important function in maintaining tissue
homeostasis. GJIC is the process in which small metabolites are shared directly by contiguous cells that
have their cytoplasms connected by aqueous channels called gap junctions. FMC2u cells expressed
both Cx43 and Cx46 (Figure 2C).
Bcl-2 is an antiapoptotic protein that is a key regulator of apoptosis [14] and associated with
low-grade, slowly proliferating, ER+ breast cancer [15,16]. Overexpression of Bcl-2 has been identified
in a variety of malignancies and is one of the 21 genes used as a prognostic signature in Oncotype
DX, a diagnostic test for the likely benefit from certain types of chemotherapy [17]. FMC2u cells were
shown to have a high expression of Bcl-2 (Figure 2C).
2.3. Effects of Treatment with Gap Junction Enhancers
A class of substituted quinolines was described in Shi et al. [9,18,19] and the effects of the first and
second generation compounds (PQ1 and PQ7, respectively) as gap junction enhancers in breast cancer
cell lines have been explored in previous studies.
2.4. Cellular Proliferation and Viability
The gap junction enhancers were tested for their inhibitory capacity on FMC2u cells. PQ1 was
shown to have an IC50 of 6.5 µM over a 24 h treatment period, while a 48 h treatment period required
an increase to 8 µM to reduce viability by 50% (Figure 3A). This suggests that the effect of PQ1 on
FMC2u cells is time and dose dependent. The effects of treatment were also seen in the total cell
count after each treatment period (Figure 3B), indicating that the proliferative ability of the cells is
compromised. PQ7 was shown to be ineffective at all concentrations tested (Data not shown).
To determine if the observed reduction in growth and viability of FMC2u cells after PQ1 treatment
was due to activation of the apoptotic pathway, the expression of cleaved caspase-3 was examined.
Apoptosis is a highly regulated cell suicide mechanism and the cleavage of protein substrates by
caspases is unique to apoptotic cells. PQ1 treatment over a 24 h period led to a significant increase in
cleaved caspase-3 expression at all concentrations tested (p-value1µM = 0.00556, p-value2.5µM = 0.00026,
p-value5µM = 0.02237; Figure 3C). This indicates that PQ1 activates apoptosis in FMC2u cells.
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24 h period; (D) Graphical representation of Cx43 protein expression in FMC2u cells treated with PQ1 
over 6, 12, 24, 36, and 48 h; (E) Gap junction activity of FMC2u determined by scrape load dye transfer 
after treatment with DMSO (control) or PQ1 at 1 µM, for 2 h. Red lines indicate a cross section cut of 
initial dye. Lucifer yellow was used as a gap junctional dye and Rhodamine-dextran used to mark the 
cut site. Green fluorescence indicates the passage of dye form the cutting site, showing GJIC. Scale 
bar = 100 µm; (F) Raw and graphical representation of the relative ZO-1 in Cx43-immunoprecipitated 
complex of FMC2u cells after treatment with 0, 1, 2.5, and 5 µM PQ1 over a 24 h period. Actin used 
as a loading control. All experiments conducted with a sample size of three. * p-value < 0.05 compared 
to DMSO control. 
2.5. Connexin Expression 
Previous studies have shown that PQ1 may induce an upregulation of Cx43 in neoplastic cells 
[20,21]. When Cx43-deficient MCF-7 breast cancer cells were transfected with Cx43, the cell-cell 
communication was restored and their malignant properties including anchorage-independent 
growth, migration and invasion were reduced, suggesting the role ofCx43 as a tumor suppressor. 
Immunoblot analysis of Cx43 expression was conducted for FMC2u cells treated with 1, 2.5, and  
5 µM PQ1 for 6, 12, 24, 36, and 48 h periods (Figure 3D). At 24 h post PQ1 exposure, Cx43 expression 
is shown to significantly increase in a linear fashion (p-value < 0.05). Interestingly, 6 h post treatment, 
2.5 and 5 µM PQ1 induced a reduction in Cx43 expression. The anticancer effects of PQ treatment on 
FMC2u cells may be due to the induced alterations in Cx43 expression. 
Figure 3. The effects of gap junction enhancer (PQ1) treatment on FMC2u. (A) Cellular viability and
(B) proliferation determined by Acridine Orange/Propidium Iodide (AO/PI) after PQ1 treatment over
either 24 or 48 h with varying concentrations; (C) Raw and graphical representation of the relative
expression of cleaved caspase-3 in FMC2u cells after treatment with 0, 1, 2.5, and 5 µM PQ1 over a
24 h period; (D) Graphical representation of Cx43 protein expression in FMC2u cells treated with PQ1
over 6, 12, 24, 36, and 48 h; (E) Gap junction activity of FMC2u determined by scrape load dye transfer
after treatment with DMSO (control) or PQ1 at 1 µM, for 2 h. Red lines indicate a cross section cut of
initial dye. Lucifer yellow was used as a gap junctional dye and Rhodamine-dextran used to mark the
cut site. Green fluorescence indicates the passage of dye form the cutting site, showing GJIC. Scale
bar = 100 µm; (F) Raw and graphical representation of the relative ZO-1 in Cx43-immunoprecipitated
complex of FMC2u cells after treatment with 0, 1, 2.5, and 5 µM PQ1 over a 24 h period. Actin used as
a loading control. All experiments conducted with a sample size of three. * p-value < 0.05 compared to
DMSO control.
2.5. Connexin Expression
Previous studies have shown that PQ1 may induce an upregulation of Cx43 in neoplastic
cells [20,21]. When Cx43-deficient MCF-7 breast cancer cells were transfected with Cx43, the cell-cell
communication was restored and their malignant properties including anchorage-independent growth,
migration and invasion were reduced, suggesting the role ofCx43 as a tumor suppressor. Immunoblot
analysis of Cx43 expression was conducted for FMC2u cells treated with 1, 2.5, and 5 µM PQ1 for 6, 12,
24, 36, and 48 h periods (Figure 3D and Supplemental Figure S1). At 24 h post PQ1 exposure, Cx43
expression is shown to significantly increase in a linear fashion (p-value < 0.05). Interestingly, 6 h post
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treatment, 2.5 and 5 µM PQ1 induced a reduction in Cx43 expression. The anticancer effects of PQ
treatment on FMC2u cells may be due to the induced alterations in Cx43 expression.
2.6. Gap Junctional Intercellular Communication (GJIC)-Dependent Effect: GJIC and Connexin
Protein Binding
To determine functionality of the gap junctions scrape load dye transfer was performed on FMC2u
cells with either control (DMSO) or 1 µM PQ1 for 2 h (Figure 3E). The untreated FMC2u cells have
functional GJIC, seen from the passage of dye from the cut site to cells further away. PQ1 treatment
increased the distance of dye transfer 2.453-fold, indicating an increase in GJIC. The anticancer effects
of PQ treatment on FMC2u cells may be due to alterations in Cx43 expression.
Cx43 plays a role in protein binding, specifically to zona occludens-1 (ZO-1). The C-terminal
domain of Cx43 contains several phosphorylation sites with signaling motifs which binds to the PDZ
domain of ZO-1 [22]. Previous studies showed that endogenous Cx43 and ZO-1 colocalized at the
gap junctions [22], suggesting that ZO-1 recruits signaling proteins into the gap junction channel.
Immunoprecipitation of Cx43 led to the quantification of bound ZO-1. PQ1 treatment of FMC2u cells
resulted in an increase in ZO-1 after 24 h of treatment independent of concentration (p-value < 0.05;
Figure 3F). The observed increase in bound ZO-1 to Cx43 indicates an increase in signaling molecules
recruited to the gap junction. This data indicates that PQ1 has a GJIC-dependent mechanism of action.
2.7. GJIC-Independent Effect: MAPK Signaling
To determine if PQ1 had affected GJIC-independent apoptotic signaling, alterations in the
expression of multiple players in the MAPK pathway were identified. Treatment of 5 µM PQ1 induced
a significant increase in cRaf expression (Figure 4A). This suggests that PQ1 treatment modulates cRaf
expression. Raf kinases are best known as key regulators of the MEK/ERK cascade, and up-regulated
signaling through the RAF/MEK/ERK pathway has an important role in cancer [23,24]. Changes
in the phosphorylation levels of key proteins in the RAF/MEK/ERK pathway were determined by
Western blot analysis. PQ1 treatment over a 24 h period induced an increase in phospho-p44/42-MAPK
at 2.5 and 5 µM PQ1 (p-value = 0.02606 and 0.00946, respectively; Figure 4B). There were no changes in
p44/42-MAPK expression due to PQ1 treatment or transfection experiments. This data indicates PQ1
indirectly alters the ERK1/2 signaling cascade.
Int. J. Mol. Sci. 2016, 17, 178 6 of 19 
 
2.6. Gap Junctional Interce lular Communication (GJIC)-Dependent Effect: GJIC and Co nexin  
Protein Binding 
To determine functionality of the gap ju ctions scrape load dye transfer was performed on 
FMC2u cells with either control (DMSO) or 1 µM PQ1 for 2 h (Figure 3E). The untreated FMC2u cells 
have functional GJIC, seen from the passage of dye from the cut site to cells further away. PQ1 
treatment increased the distance of dye transfer 2.453-fold, indicati g an increase in GJIC. The 
anticancer effects of PQ treatment on FMC2u cells may be due to alterations in Cx43 expression. 
Cx43 plays a role in protein binding, specifically to zona occludens-1 (ZO-1). The C-terminal 
domain of Cx43 contains several phosphorylation sites with signaling motifs which binds to the PDZ 
domain of ZO-1 [22]. Previous studies showed that endogenous Cx43 and ZO-1 colocalized at the 
gap junctions [22], suggesting that ZO-1 recruits signaling proteins into the gap junction channel. 
Immunoprecipitation of Cx43 led to the quantification of bound ZO-1. PQ1 treatment of FMC2u cells 
resulted in an increase in ZO-1 after 24 h of treatment independent of concentration (p-value < 0.05; 
Figure 3F). The observed increase in bound ZO-1 to Cx43 indicates an increase in signaling molecules 
recruited to the gap junction. This ata in icates that 1 as a JI - e e e t ec a is  f acti . 
2.7. GJIC-Independent Effect: MAPK Signaling 
To determine if PQ1 had affected GJIC-independent apoptotic signaling, alterations in the 
expression of multiple players in the MAPK pathway were identified. Treatment of 5 µM PQ1 
induced a significant increase in cRaf expression (Figure 4A). This suggests that PQ1 treatment 
modulates cRaf expression. Raf kinases are best known as key regulators of the MEK/ERK cascade, 
and up-regulated signaling through the RAF/MEK/ERK pathway has an important role in cancer 
[23,24]. Changes in the phosphorylation levels of key proteins in the RAF/MEK/ERK pathway were 
determined by Western blot analysis. PQ1 treatment over a 24 h period induced an increase in 
phospho-p44/42-MAPK at 2.5 and 5 µM PQ1 (p-value = 0.02606 and 0.00946, respectively; Figure 4B). 
There were no changes in p44/42-MAPK expression due to PQ1 treatment or transfection 
experiments. This data indicates PQ1 indirectly alters the ERK1/2 signaling cascade. 
 
Figure 4. Cont. 
Figure 4. Cont.
Int. J. Mol. Sci. 2016, 17, 178 7 of 19
Int. J. Mol. Sci. 2016, 17, 178 7 of 19 
 
 
Figure 4. Expression of signaling molecules after treatment with PQ1. Raw and graphical 
representation of (A) cRaf; (B) p44/42 MAPK (P: phosphorylated); (C) p38 MAPK (P: phosphorylated), 
and (D) Bcl-2 in FMC2u cells after treatment with 0, 1, 2.5, and 5 µM PQ1 over a 24 h period. Actin 
used as a loading control. All experiments conducted with a sample size of three. * p-value < 0.05 
compared to DMSO control. 
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cascade, suggesting a MAPK-dependent pathway of apoptosis. 
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Figure 4. Expression of signaling molecules after treatment with PQ1. Raw and graphical representation
of (A) cRaf; (B) p44/42 MAPK (P: phosphorylated); (C) p38 MAPK (P: phosphorylated), and (D) Bcl-2
in FMC2u cells after treatment with 0, 1, 2.5, and 5 µM PQ1 over a 24 h period. Actin used as a
loading control. All experiments conducted with a sample size of three. * p-value < 0.05 compared to
DMSO control.
Another MAPK family member is the stress-activated protein kinase (p38-MAPK). PQ1 treatment
over a 24 h period induced an increase in phosphorylated p38-MAPK when exposed to 2.5 and
5 µM PQ1 (p-value = 0.01545 and 0.03686, respectively; Figure 4C). There were no changes in
p38-MAPK expression after PQ1 treatment. PQ1, therefore, indirectly alters p38-MAPK signaling
cascade, suggesting a MAPK-dependent pathway of apoptosis.
Expression of the antiapoptotic protein Bcl-2 was next determined. This molecular marker is
part of a group of antiapoptotic proteins that have been shown to be an important factor in the
development of apoptotic resistance. Previous studies have demonstrated that MAPK pathway is
active in Bcl-2 overexpressing cancer cells under stressful conditions [25]. Bcl-2 phosphorylation by
activated p38-MAPK is a key event in the early induction of apoptosis under conditions of cellular
stress [26]. PQ1 has been reported to induce apoptosis in human breast cancer cells through the
upregulation of caspases and an alteration in Bax/Bcl-2 expression ratio [21,27]. Exposure to 2 and
5 µM PQ1 induced a significant reduction in Bcl-2 expression in FMC2u cells (p-value = 0.00968;
Figure 4D). PQ1 treatment affects apoptotic signaling through Bcl-2 expression, possibly due to
increased phosphorylation of p38-MAPK.
2.8. The Effects of Modulating Connexin 43 Protein Expression
To determine if the anti-proliferative and apoptotic effects of PQ1 treatment were due to the
observed change in Cx43 expression, FMC2u cells were transfected with Cx43 cDNA to induce
overexpression. Overexpression of Cx43 was successfully accomplished with an approximate threefold
increase in protein expression at 6 h post transfection (Figure 5A). The effects of reduced Cx43
expression were also examined by the transfection of Cx43 siRNA, which successfully silenced
approximately 65% of expression at 24 h post transfection (Figure 5B).
2.9. Cellular Proliferation and Viability
Overexpression of Cx43 in FMC2u cells had an 86% viability at 6 h post transfection
(p-value = 0.0037) and remained significantly lower than control cells (Figure 5C). However,
silencing of Cx43 by siRNA had a 5% increase in cell viability at 48 h post transfection (p-value
= 0.0203, Figure 5C). The total cell count was increased at 36 h post-transfection of Cx43
(p-value = 0.0150; Figure 5D). Silencing of Cx43 reduced total number of cells at 24 and 36 h
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(p-value24h = 0.0107 and p-value36h = 0.0203; Figure 5D). Modulation of Cx43 expression significantly
affects the growth and viability of FMC2u cells.Int. J. Mol. Sci. 2016, 17, 178 8 of 19 
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Figure 5. Modulation of connexin 43 expression affects proliferation and viability of FMC2u cells.
(A) Graphical representation of fold protein induction from western blot analysis of Cx43 in FMC2u
cells transfected with GFP-Cx43 cDNA vectors; (B) Graphical representation of fold protein induction
from western blot analysis of Cx43 in FMC2u cells transfected with siRNA of Cx43; (C) Viability
and (D) Total cell count either overexpressing (OE) Cx43 or with silenced (siRNA) Cx43 compared to
normal unmodified cells; (E) Graphical representation of cleaved caspase-3 expression in FMC2u cells
post transfection. All experiments conducted with a sample size of n = 3. * p-value < 0.05 compared to
respective transfection control.
The expression of cleaved caspase-3, a ubiquitously distributed caspase and the main effector
caspase of apoptosis, was determined post transfection of FMC2u cells. Overexpression of Cx43 via
transfection of cDNA significantly increased expression of cleaved caspase-3 at 6, 12, and 24 h post
transfection (p-value6h = 0.0088, p-value12h = 0.04275, p-value24h = 0.01769; Figure 5E). Silencing of
Cx43 significantly increased cleaved caspase-3 expression at 24 h post transfection (p-value = 0.035;
Figure 5E). Both the overexpression and silencing of Cx43 led to activation of apoptosis in FMC2u
cells. This suggests that Cx43 is highly regulated within the cell, and variation in expression levels can
trigger cell suicide.
2.10. GJIC-Dependent Effect: GJIC and Connexin Protein Binding
To confirm that the overexpression of Cx43 led to functional gap junctions, scrape load dye
transfer was conducted. Figure 6A shows an increase in dye transfer in FMC2u cells overexpressing
Int. J. Mol. Sci. 2016, 17, 178 9 of 19
Cx43 compared to control cells. Additionally the silencing of Cx43 resulted in reduced dye transfer in
FMC2u cells, indicating a loss of GJIC (Figure 6A). This suggests that exogenous Cx43 assists in the
formation of functional gap junctions in FMC2u cells.Int. J. Mol. Sci. 2016, 17, 178 9 of 19 
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2.11. GJIC-Independent: MAPK Signaling 
To determine if Cx43 plays a role in GJIC-independent apoptotic signaling, alterations in the 
expression of multiple players in the MAPK pathway were identified (Figure 7A). When Cx43 is 
overexpressed through cDNA, cRaf expression was also significantly upregulated, while silencing 
Figure 6. Modulation of connexin 43 expression affects GJIC. (A) Gap junction activity of FMC2u
determined by scrape load dye transfer after transfection with empty vector (control), GFP-Cx43
cDNA vector, or siRNA Cx43. A graphical representation of dye transfer in µm was shown next to the
images. Red lines indicate a cross sectional cut. Lucifer yellow was used as a gap junctional dye and
Rhodamine-dextran used to mark the cut site. Green fluorescence indicates the passage of dye form
the cutting site. Images taken at 4ˆ, 10ˆ, and 20ˆ. Scale bar = 100, 100, 50 µm, respectively. Graphical
representation of ZO-1 expression in Cx43-immunoprecipitated FMC2u cells at 0, 6, 12, 24, 36, and 48 h
post transfection; (B) Induced overexpression of Cx43 and (C) a silencing of Cx43. All experiments
conducted with a sample size of n = 3. * p-value < 0.05 compared to respective transfection control.
Modulation of Cx43 protein expression through transfection experiments induced alterations
in ZO-1 expression. Immunoprecipitation of Cx43 led to the quantification of bound ZO-1. Cx43
overexpression led to a significant increase in ZO-1 binding at all experimental time points (Figure 6B).
Cells transfected with Cx43 siRNA had little to no effect on ZO-1 expression and binding, only at 12 h
post transfection was ZO-1 binding significantly altered Figure 6C). The observed increase in bound
ZO-1 to Cx43 in the overexpressing-Cx43 cells suggests an increase in the recruitment of signaling
molecules to the gap junction.
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2.11. GJIC-Independent: MAPK Signaling
To determine if Cx43 plays a role in GJIC-independent apoptotic signaling, alterations in the
expression of multiple players in the MAPK pathway were identified (Figure 7A). When Cx43 is
overexpressed through cDNA, cRaf expression was also significantly upregulated, while silencing
Cx43 induced a significant reduction in cRaf expression (Figure 7B). This suggests that Cx43 modulates
cRaf expression.
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Figure 7. Altering connexin 43 affects expression of signaling molecules involved in cellular survival.
(A) Raw and (B–E) graphical representation of western blot analysis of cRaf, phosphorylated (P) and
unphosphorylated MAPK (p44/42 and p38), and Bcl-2 expression levels relative to loading control
in FMC2u cells transfected with either cDNA of Cx43 to induce overexpression (L ft) or siRNA to
silence Cx43 (right). Actin used as a loading control. n = 3. * p-value < 0.05 compared to respective
transfection control.
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Overexpression of Cx43 significantly reduced the level of phosphorylated p44/42-MAPK at 24
and 36 h post transfection (p-value = 0.04324 and 0.01349, respectively; Figure 7C). With silencing of
Cx43 via siRNA there was a significant increase in the phosphorylation of p44/42-MAPK at 6 and 12 h
post transfection (p-value = 0.00219 and 0.00355, respectively; Figure 7C). There were no changes in
p44/42-MAPK expression. This data indicates Cx43 indirectly alters the ERK1/2 signaling cascade,
suggesting a role for Cx43 in the regulation of proliferation through ERK1/2 signaling.
Due to overexpression of Cx43 there was a corresponding increase in phosphorylated p38-MAPK
expression at 6 and 12 h post transfection (p-value =0.00649 and 0.00301, respectively; Figure 7D).
Silencing of Cx43 via siRNA led to a reduction in the phosphorylation of p38-MAPK at 6 h post
transfection (p-value = 0.04942; Figure 7D). There were no changes in p38-MAPK expression due Cx43
silencing. This data indicates Cx43 indirectly alters the p38-MAPK signaling cascade, suggesting a
MAPK-dependent pathway of apoptosis.
Overexpression of Cx43 significantly reduced Bcl-2 expression at 6, 12, and 24 h post transfection
(p-value < 0.05; Figure 7E). Additionally, the silencing Cx43 induced a significant increase in Bcl-2
expression at 48 h post transfection (p-value = 0.03119; Figure 7E). This indicates that altering
Cx43 expression affects apoptotic signaling through Bcl-2 expression, most likely due to increased
phosphorylation of p38-MAPK.
3. Discussion
In this study, the female mammary carcinoma cell line FMC2u, derived from a MMTV-PyVT
transgenic mouse, was established and characterized over multiple passages. FMC2u cells are adherent
cells of epithelial origin that proliferate rapidly. Growth characteristics and protein analysis suggests
that these cells represent an advanced stage of mammary carcinoma in a mouse model. FMC2u cells
have been shown to both migrate across an adherent surface and transverse a membrane with 8 micron
pores, indicating a more invasive neoplastic cell line. FMC2u cells are highly proliferative with a
doubling time of 24 h. This is a rapidly growing cell line with greater proliferative ability than MCF-7,
T47D, MDA-MB-453, and MDA-MB-231 breast cancer cell lines, which double at 29, 36, 47, and 38 h
respectively. The more proliferative the cell line, the more rapidly the tumor grows, and a tendency to
have a poorer prognosis.
Hormone receptor profiles are useful diagnostic tools and predictors of therapeutic response.
FMC2u were determined to express low levels of ER and PR, with high expression of HER2. These
cells can be considered HER2 + high/ER + low/PR + low. ER is expressed in approximately 80%
of all breast cancers [28], while overexpression of HER2 or both are present in about 15% of breast
cancers [29]. HER2 overexpression is associated with partial resistance to endocrine treatment [30,31],
suggesting that this cell line would be unresponsive to endocrine therapy. Additionally, RAS signaling
pathways are commonly activated in tumors in which growth-factor-receptor tyrosine kinases, such
as HER2, have been overexpressed. Aberrant overexpression or mutational activation of receptor
tyrosine kinases can cause hyperactivation of Ras leading to upregulated MAPK signaling [32–34]. The
overexpression of HER2 may enhance the MAPK signaling cascade, making this cell line appropriate
for MAPK specific research.
Impaired gap junctional intercellular communication (GJIC) has been reported in vivo in many
human tumors [35,36] and in vitro in response to oncogenes [37] or tumor promoters [38]. Primary
tumors that are initially GJIC impaired become GJIC competent during the metastatic stage [4].
Increased expression of connexins and GJIC correlate with invasiveness and metastasis in a variety of
cancer cell types, including breast cancer. Connexin expression profiles change from a metastatic cell
to that more similar to a normal breast epithelial cell with expression of metastasis-suppressor gene
BRMS1 [39]. This suggests that the connexin composition of gap junctions contributes to the lesions
metastatic potential. FMC2u cells were shown to be GJIC competent with strong expression of Cx43.
Previous data presented suggests that Cx43 and Cx46 are upregulated during late tumor development
and metastasis in the parental transgenic mouse model [20]. The report also demonstrated that
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expression of HER2 at the three stages of tumor development is higher in the Early and Late stages
than the Pre stage. Furthermore, examination of connexins in 96 breast cancer patients showed that
pre-chemotherapy Cx43 expression correlated positively with hormone receptor status both before
and after chemotherapy and had a negative correlation with HER2 expression pre-chemotherapy [40].
These findings suggest that there is a negative correlation between Cx43 and HER2 expression.
PQ1 was shown to have an IC50 of 6.5 µM over a 24 h treatment period. This concentration is
6.5 times that needed to inhibit T47D growth [9], indicating the FMC2u are more resistant to treatment
than other cells lines tested. PQ1 is considered a gap junction enhancer due to the observed increase in
GJIC and upregulation of connexin expression [9,20,21]. Here, PQ1 treatment of FMC2u cells resulted
in the upregulation of Cx43, with a decrease in cellular viability and proliferation rate. This may be
explained by the overexpression of Cx43 induced by PQ1. The role of Cx43 both as a gap junctional
component and independent of GJIC was examined in FMC2u cells with the goal of providing insight
into the mechanism behind the anticancer effects of PQ1.
Overexpression by transfection of several connexins, such as Cx43 in tumor and transformed
cells, has been shown to inhibit tumorigenicity, leading to the notion that connexins behave like
tumor suppressor genes and may be involved in physiological and/or tumor cell growth [41,42]
given the critical role of Cx43 expression. Transfection experiments conducted indicate that a
reduction in connexin expression slows neoplastic cell proliferation, while an increase in connexin
expression reduces viability. This suggests that there are multiple pathways affected by alterations in
Cx43 expression.
Connexins can interact with a large number of scaffolding and signaling proteins that are involved
in the regulation of GJIC [43,44]. ZO-1 is a major connexin interacting protein needed for stability of
Cx43 at the plasma membrane and endocytosis of the gap junction [45–47]. Disruption of ZO-1-Cx43
interaction in osteosarcoma cells has been shown to lead to a decreased in GJIC and delocalized
Cx43, while overexpression of ZO-1 increases GJIC and membranous Cx43 [48]. The dissociation of
ZO-1 from Cx43 results in gap junction endocytosis, indicating that Cx43 internalization is a ZO-1
dependent process [49]. Here, we show that ZO-1 is bound to Cx43, indicating functional gap junction
plaques in FMC2u cells. The observed increase in ZO-1 with Cx43 overexpression suggests an increase
in recruitment of signaling molecules towards the gap junction and thus an increase in GJIC. This
indicates that the upregulation of connexin expression by PQ1 treatment leads to an increase in ZO-1
binding and GJIC. PQ1 has a GJIC-dependent mechanism of action.
Connexins have been shown to be tumor suppressors, but rather than being dependent
on cell coupling activity, this effect has also been linked to connexin species-specificity [41,50].
Connexin-transfected cells with inhibition of cellular growth and tumor suppression lack gap
junction assembly on the cell membrane [51] and have cytoplasmic and nuclear localized connexin
expression [41,52], indicating gap junctions and hemichannels are not involved. Additionally, only
the c-terminal domain of specifically Cx43 has been shown to be vital for growth suppression [53,54].
These data suggest that expression of connexins, rather than GJIC, corresponds to the regulation of
neoplastic growth and suppression. Further study will be explored into the GJIC-independent role of
Cx43 in relation to PQ1 cytotoxicity in FMC2u cells.
The mitogen-activated protein kinase (MAPK) signaling pathways are crucial for the maintenance
of the cells. There are three subfamilies of MAPKs: extracellular signal-regulated kinases (ERKs,
p44/42 MAPK), c-Jun N-terminal kinases (JNKs), and p38-MAPKs. In general, ERKs are important for
cellular proliferation and survival, while JNKs and p38-MAPKs respond to stress stimuli to induce
apoptosis [55]. First we observed the expression of cRaf, a protooncogene product that is a main
component of many signaling pathways involved in normal cellular proliferation and oncogenic
transformation [56]. Upon activation, cRaf phosphorylates the mitogen-activated protein kinase kinase
(MEK), which then can activate p44/42 MAPK which propagates the signals [56]. PQ1 treatment led to
an upregulation of cRaf expression and a corresponding increase in the activation of p44/42 MAPK,
indicating an increase in the ERK1/2 signaling cascade. Unexpectedly, the overexpression of Cx43 led
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to a different result, in which there was an upregulation of cRaf, but a reduction in activation of p44/42
MAPK. This suggests that PQ1 has a Cx43-independent effect on the ERK1/2 signaling cascade.
Transfection of Cx43 siRNA induced a reduction in GJIC while leading to a decrease in cRaf
expression, but an activation of p44/42 MAPK. This is the opposite of what was seen in overexpression
experiments, indicating that Cx43 may play a role in the regulation of ERK1/2 signaling, and thus
cellular growth and survival. This also supports the hypothesis that cells must be removed from a state
of growth suppression prior to mitogenic cell signaling [57]. The inhibition of GJIC has previously
been shown to precede the activation of p44/42 MAPK [58]. This is confirmed by the observation
that reduced expression of Cx43 induced a decrease in GJIC with a corresponding activation of ERK
signaling. The Raf-MEK-ERK cascade is a core element of a complex signaling network. More research
is needed to determine how Cx43 may contribute to the Raf-MEK-ERK pathway in cancer.
Recent reports have shown the PQ1 has anticancer properties as a potent chemopreventive
and chemotherapeutic compound that prevents, inhibits, and attenuates tumorigenesis [20,21,27].
The results of the present study are in agreement with the previous studies concerning activation
of apoptotic signaling with PQ1 treatment. The cytotoxicity of PQ1 may be attributed to the
upregulation of Cx43. PQ1 also led to the phosphorylation of p38-MAPK. This suggests activation of
apoptosis, which is confirmed by the cleavage of caspase-3 and reduced cellular viability. There was a
corresponding reduction in Bcl-2, indicating the cell is more susceptible to apoptotic signaling. These
results match those from transfection experiments in which Cx43 is overexpressed. Therefore, PQ1
induces apoptosis via modulation of Cx43, resulting in direct effects on tumor cell survival in a p38
MAPK-dependent manner.
The effects of treatment with the gap junction enhancer PQ1 reduced proliferation and viability,
while also inducing an upregulation in Cx43 expression in an epithelial based mammary carcinoma
cell culture derived from a malignant murine tumor. PQ1 was shown to not only affect GJIC, but
also cellular survival via a MAPK-dependent pathway. The activation of p44/42 MAPK by PQ1 was
independent of Cx43 expression, but modulation of Cx43 was shown to alter ERK signaling. This
introduces the hypothesis that Cx43 may contribute to the regulation of the ERK1/2 signaling cascade.
Additionally, Cx43 may be the key element in the mechanism of PQ1 induced apoptosis. The present
study provided the first evidence that PQ1 activates p38 MAPK in an aggressive mammary carcinoma
cell line.
Further studies will analyze the effect of Cx43 siRNA and overexpression on PQ1-induced
molecular effects, GJIC, and apoptosis. Initial finding of mechanistic link demonstrates that 5 µM PQ1
can increase Cx43 expression in prior treated cells with Cx43 siRNA (Supplemental Figure S2). Further
analysis is needed to fully examine the effect of PQ1-induced apoptosis.
4. Experimental Section
4.1. Ethics Statement
Husbandry of animals is conducted by the Comparative Medical Group (CMG) at the College
of Veterinary Medicine at Kansas State University (Manhattan, KS, USA). The CMG animal facilities
are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care,
International (AAALAC). The compliance to aspects of animal welfare law is regularly monitored by
the veterinary staff. Animal care and use protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) at Kansas State University, Manhattan following NIH guidelines.
4.2. Establishment of Cell Cultures
FMC2u cultures were derived from malignant tumors from the transgenic strain
FVB/N-Tg(MMTV-PyVT)634Mul/J. Female mice were approximately 12 weeks old with no treatment
prior to tissue removal. Whole tumors were washed with sterile PBS three times and cut in half prior to
trypsinization for 30 min at 37 ˝C. After incubation, tumors were removed and trypsin was neutralized
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with RPMI with insulin, followed by centrifugation at 2000 rpm for 5 min. Supernatant was aspirated
and cells resuspended in RPMI supplemented with insulin and 10% fetal bovine serum (FBS) and then
plated in a T-75 tissue culture flask. Cells were maintained in RPMI medium supplemented with 10%
FBS (Atlanta Biologicals, Lawrenceville, GA, USA) at 37 ˝C with 5% CO2 in T-125 flasks.
4.3. Media Test
Cells were seeded in 6-well plates in RPMI with insulin, RPMI, DMEM, DMEM/F12, MEM, or
L15. All media contained 10% FBS. Images were taken of the monolayer growth every 24 h. Once cells
were 100% confluent, cell count and viability were determined by AO/PI (see below).
4.4. Cell Doubling Time
Cell doubling times at 36 ˝C were measured by counting the number of viable cells from
trypsinized monolayers by Trypan blue exclusion. Counts were performed at 12 to 24 h intervals.
4.5. Colony Formation
100,000 cells were seeded between 0.8% agarose RPMI 10% FBS and 0.4% agarose RPMI 10%
FBS. Images were taken every 24 h to determine if individual cells could form a colony in a 3
dimensional medium.
4.6. Migration Assay
Cells were grown to 90% confluency. Two cuts crossing each other in the center of the well were
made to create a “wound” on the cell monolayer. Cells were washed with 1 mL of media and then
incubated in RPMI 10% FBS at 37 ˝C. Images were taken every 12 h until the wound was closed and
cells were confluent.
4.7. Invasion Assay
Cells were seeded into the upper chamber of a transwell with RPMI 0% FBS. The lower chamber
contained RMPI 10% FBS. Cells were incubated for varying time points (24, 48, 72 h) and the number
of cells in the lower chamber were counted by Trypan blue.
4.8. Cell Recovery
Cells were frozen down using 500 µL of cell culture freezing medium from Invitrogen
(Cat. # 12648-010; Life Technologies, Grand Island, NY, USA) and allowed to sit at ´20 ˝C for 1 h prior
to exposure to ´80 ˝C. Cryovials were removed from ´80 ˝C storage and rapidly thawed with warm
media. Cells were gently agitated. Samples were transferred to 15 mL conical tubes and 5 mL of warm
media was added. Cells were allowed to incubate for 10 min at 37 ˝C, followed by centrifugation
(5 min at 2000 rpm). Supernatant was aspirated out and cells resuspended in PBS and Trypan Blue for
viability testing.
4.9. Antibodies
Antibodies against cleaved caspase 3, Cx43, Cx46, ER (α and β), PR, and Bcl-2 (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), phospho-p42/44 MAP kinase, cRaf, and HER2 (Cell Signaling,
Boston, MA, USA), and actin (Sigma-Aldrich, St. Louis, MO, USA) were used.
4.10. Western Blot Assay
Whole cell extractions conducted using lysis buffer (20 mM Tris pH 7.5, 0.5 mM EDTA,
0.5 mM EGTA, and 0.5% Triton X-100) with 1:1000 dilution of protease inhibitors (Sigma-Aldrich, Saint
Louis, MO, USA). Tissue was sonicated, followed by centrifugation at 13,000 rpm for 30 min at 4 ˝C.
Twenty-five µg of whole-cell extract was resolved by 10% SDS polyacrylamide gel electrophoresis
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(PAGE) and transferred to nitrocellulose membrane (Midwest Scientific, Saint Louis, MO, USA).
Nitrocellulose membrane was blocked in 5% milk for an hour at room temperature and then incubated
with monoclonal antibodies at a dilution of 1:1000. Western blots were detected by enhanced
chemiluminescence detection reagents (Pierce, Rockford, IL, USA) and visualized by Fluorochem E
imaging system (ProteinSimple, San Jose, CA, USA).
4.11. Immunoprecipitation Assay
For immunoprecipitation 1 mg of total protein was precleared with 10 µL of IgG and 10 µL
protein A/G agarose beads (sc-2003, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Samples were
incubated at 4 ˝C for 30 min, followed by centrifugation at 1500 rpm for 5 min to pellet the IgG agarose
conjugate. Five microliters of primary antibody were added to each sample and incubated at 4 ˝C
overnight. This was followed by addition of 20 µL protein A/G agarose beads and 2 h incubation.
Sample was centrifuged at 1500 rpm for 5 min to pellet the primary antibody agarose conjugate.
Supernatant was removed and remaining pellet used for Western blot analysis.
4.12. Treatment with Gap Junction Enhancers
Compound PQ1, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethyl-phenyloxy)
quinolines, was prepared by following the reported procedure [18]. Cells were seeded into 6-well
plates in RPMI 10% FBS and allowed to attach overnight. Cells dosed with varying concentrations of
each compound in RPMI 0% FBS for 24, 48, or 72 h.
4.13. Overexpression and Silencing of Connexins
cDNA from human Cx43 was purchased from Addgene (Cambridge, MA, USA; plasmid #40907).
Connexin 43 siRNA (sc-35091) was purchased from Santa Cruz Biotechnolgoy (Santa Cruz, CA,
USA). Connexin 46 siRNA (S100131670) was purchased from Qiagen (Germantown, MD, USA).
DNA and siRNAs were transfected according to the manufacturer’s specifications using Polyplus
(Illkirch, France) jetPEI-FluoR (106-05N) and Mirus (Madison, WI, USA) TransIT-siQUEST (MIR 2114)
transfection reagent, respectively. Briefly, cells were cultured in six-well plates and incubated under
their normal growth conditions. When cells reached 50% confluency, 5 µg of DNA or 3.2 µg of siRNA
complex was mixed with transfection reagent and incubated at room temperature for 15 min prior
to applying to the cells. Cells were either utilized for in vitro experimentation or the cell lysates were
collected and prepared for Western blot analysis.
4.14. Proliferation and Viability
Post treatment period, the media was removed and saved. The cells were trypsinized for 5 min
at 37 ˝C. Cells were scraped off the plate and transferred to the saved media. Wells were washed
with 3 mL of PBS and elution was saved. Media, cells, wash were centrifuged for 4 min at 2000 rpm.
Supernatant was aspirated and cells resuspended in PBS. A cell sample was mixed with Acridine
Orange/Propidium Iodide (AO/PI) at a 1:1 ratio. Cell count and viability was determined by Nexcelom
(Lawrence, MA, USA) cell counter.
4.15. Scrape Load Dye Transfer
Cells were grown to 90% confluency on coverslips in 6-well plates. Cells were washed three times
with PBS. The 2.5 µL mixture of 1% (w/v) Lucifer yellow and 0.75% (w/v) of Rhodamine-dextran was
added in the center of the coverslip. Two cuts crossing each other in the center of the coverslip were
made. After 3 min, cells were washed three times with PBS and incubated at 37 ˝C in tissue culture
media for 20 min. The cells were then washed with PBS and fixed in 2.5% paraformaldehyde for
10 min. Cells were mounted on a slide, sealed and visualized under a fluorescence microscope at 10ˆ
objective. Three independent experiments with sample size of 3 per each treatment were performed.
Int. J. Mol. Sci. 2016, 17, 178 16 of 19
4.16. Statistical Analysis
Significance was considered at a p-value ď0.05 using Student’s t-test analysis. All data are
presented as mean ˘95% confidence interval of at least three independent experiments.
5. Conclusions
A novel cell line, FMC2u, from the primary tumor with an aggressive, metastatic phenotype
was used to evaluate the role of Cx43 in PQ1-induced cytotoxicity. The findings show that PQ1
decreased cell viability and proliferation and induced upregulation of Cx43. Furthermore, PQ1 exerts
GJIC-independent effects by modulating ERK1/2 and p38-MAPK signaling and by decreasing the
expression of Bcl-2 and increasing the cleavage of pro-caspase-3. However, overexpression of Cx43
resulted in reduced expression of p44/MAPK, while PQ1 treatment had the opposite effect, which
suggests that PQ1 affects the Raf-MEK-ERK cascade independent of Cx43 upregulation. Therefore, the
mechanism behind PQ1-induced cytotoxicity in FMC2u is likely due to the change in Cx43 expression.
PQ1-induced apoptosis through the upregulation of Cx43 may depend on p38 MAPK, highlighting
that the effect of PQ1 on gap junctions as well as cellular survival via a MAPK-dependent pathway.
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